News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Italy To Fund Unapproved Use Of Roche (RHHBY) Drug To Cut Costs; Move Startles The Industry


6/12/2014 6:06:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Italy will pay for patients to use Roche Holding AG’s (ROG) cancer drug Avastin to treat an eye condition for which it’s not approved as the country looks to rein in medical costs.

The decision today by the Italian Medicines Agency will steer patients with age-related macular degeneration away from Lucentis, a similar but more expensive drug developed by Roche and sold by Novartis AG (NOVN) in Italy that regulators cleared for the same disease. The country’s antitrust authority this year accused the companies of colluding to block the use of Avastin for the eyes, and the government is seeking 1.2 billion euros ($1.6 billion) in damages from them.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES